UK
coronavirus testing capacity boosted by new AstraZeneca,
GSK lab
Send a link to a friend
[April 08, 2020]
LONDON (Reuters) - Britain will have a new
coronavirus testing facility capable of carrying out 30,000 tests per
day by early May, said the chief executive of pharma company
AstraZeneca, helping the government meet an ambitious goal to scale up
testing.
|
AstraZeneca
CEO Pascal Soriot also told BBC Radio on Wednesday that an antibody
test would be ready in May.
The government last week promised a tenfold increase in the number
of daily tests to 100,000 by the end of April after facing criticism
for failing to roll out mass checks to help curb the spread of
coronavirus.
AstraZeneca is working with rival UK pharma giant GSK and the
University of Cambridge on a joint project to develop a new lab in
Cambridge, eastern England, to boost Britain's testing capacity.
"We believe we will start testing by mid-April and be at scale
indeed with 30,000 tests a day by early May," Soriot said.
Tests are seen as essential for fighting the virus and nursing the
economy back to health by allowing those with immunity to return to
work, and the UK is now trying to catch up with countries like
Germany which tests 500,000 people a week.
An antibody test, a tool which is touted by governments in Britain
and elsewhere as critical to easing nationwide lockdowns without
helping the virus to spread, being developed by AstraZeneca will
also be ready in May, Soriot said.
Scientists in Cambridge were working on a homegrown test, he said,
using some imported parts.
[to top of second column] |
Millions of antibody tests which Britain had provisionally ordered were said to
not deliver accurate results, but asked about the accuracy of AstraZeneca's
test, Soriot said: "So far, so good, we are confident".
Antibody tests show whether people have been infected with the novel coronavirus
and developed immunity - potentially allowing them to return to their places of
work.
Britain is now in its third week of lockdown, and due to enter what scientists
say will be the deadliest phase of its coronavirus epidemic, which has already
killed 6,159 people and put its Prime Minister Boris Johnson in intensive care.
AstraZeneca, GSK and Cambridge said in a statement that the new lab was also
exploring the use of alternative chemical reagents for test kits to overcome
supply shortages, and trying to help existing testing facilities expand their
capacity by using automation and robotics.
(Reporting by Sarah Young; editing by Michael Holden)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |